| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 80, 2198-2202, Copyright © 1995 by Endocrine Society
ARTICLES |
Y Higashi, T Oshima, N Ono, H Hiraga, M Yoshimura, M Watanabe, H Matsuura, M Kambe and G Kajiyama
First Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
The iv administration of L-arginine, a precursor of endothelium-derived relaxing factor/nitric oxide, is known to decrease blood pressure in humans by its direct vasodilatory effects. The purpose of the present study was to determine whether L-arginine infusion modifies the renin- angiotensin (Ang)-aldosterone system as well as blood pressure and renal hemodynamics. L-Arginine and saline vehicle were iv administered to 10 healthy male subjects in random order on different days. L- Arginine infusion (500 mg/kg over 30 min) decreased mean blood pressure (from 81.2 +/- 2.7 to 74.0 +/- 2.5 mm Hg; P < 0.001) and renal vascular resistance (from 0.085 +/- 0.007 to 0.074 +/- 0.006 mm Hg/mL.min; P < 0.01) and increased heart rate (from 60.3 +/- 2.7 to 69.7 +/- 2.1 beats/min; P < 0.001) and renal plasma flow (from 616.6 +/- 37.8 to 701.0 +/- 49.2 mL/min; P < 0.05). L-Arginine reduced serum Ang- converting enzyme activity (from 10.4 +/- 0.6 to 8.9 +/- 0.5 nmol/mL.min; P < 0.05) and plasma Ang-II (from 19.3 +/- 3.3 to 12.7 +/- 2.8 pg/mL; P < 0.001), but had no effect on PRA or the glomerular filtration rate. The saline vehicle did not alter any of these parameters. The iv administration of L-arginine (endothelium-derived relaxing factor/nitric oxide) may reduce the plasma Ang-II concentration by inhibiting Ang-converting enzyme. The mechanism by which L-arginine infusion decreases blood pressure can be at least in part explained by inhibition of the renin-Ang system.
This article has been cited by other articles:
 |
|
 |
|
  N. N. Huynh, K. L. Andrews, G. A. Head, S. M.L. Khong, D. N. Mayorov, A. J. Murphy, G. Lambert, H. Kiriazis, Q. Xu, X.-J. Du, et al. Arginase II Knockout Mouse Displays a Hypertensive Phenotype Despite a Decreased Vasoconstrictory Profile Hypertension, August 1, 2009; 54(2): 294 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ruiz, P. Singh, S. C. Thomson, K. Munger, R. C. Blantz, and F. B. Gabbai L-arginine-induced glomerular hyperfiltration response: the roles of insulin and ANG II Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1744 - R1751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tripatara, N. S.A. Patel, A. Webb, K. Rathod, F. M.J. Lecomte, E. Mazzon, S. Cuzzocrea, M. M. Yaqoob, A. Ahluwalia, and C. Thiemermann Nitrite-Derived Nitric Oxide Protects the Rat Kidney against Ischemia/Reperfusion Injury In Vivo: Role for Xanthine Oxidoreductase J. Am. Soc. Nephrol., February 1, 2007; 18(2): 570 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Gokce L-Arginine and Hypertension J. Nutr., October 1, 2004; 134(10): 2807S - 2811S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Yan, D. Kim, T. Aizawa, and B. C. Berk Functional Interplay Between Angiotensin II and Nitric Oxide: Cyclic GMP as a Key Mediator Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 26 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tousoulis, C. Antoniades, C. Tentolouris, G. Goumas, C. Stefanadis, and P. Toutouzas L-Arginine in cardiovascular disease: dream or reality? Vascular Medicine, August 1, 2002; 7(3): 203 - 211. [Abstract] [PDF]
|
|
|
|
|
|
J. L. Andersen, N. C. F. Sandgaard, and P. Bie Volume expansion during NOS substrate donation with L-arginine: regulatory offsetting of renal response? Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2002; 282(4): R1149 - R1155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. lannuzzi, G. Jannuzzo, C. Sapio, P. Pauciullo, D. Jorio, N. Spampinato, M. Mancini, and P. Rubba L-Arginine Improves Post-Ischemic Vasodilation in Coronary Heart Disease Patients Taking Vasodilating Drugs Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 121 - 127. [Abstract] [PDF]
|
|
|
|
|
|
G. Wu and C. J. Meininger Arginine Nutrition and Cardiovascular Function J. Nutr., November 1, 2000; 130(11): 2626 - 2629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Abreu, H. A. Futuro-Neto, A. M. Cabral, and E. C. Vasquez L-Arginine Restores the Effect of Ouabain on Baroreceptor Activity and Prevents Hypertension Hypertension, October 1, 1999; 34(4): 729 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Kanaya, M Nakamura, N Kobayashi, and K Hiramori Effects of L-arginine on lower limb vasodilator reserve and exercise capacity in patients with chronic heart failure Heart, May 1, 1999; 81(5): 512 - 517. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Kurtz and C. Wagner Role of nitric oxide in the control of renin secretion Am J Physiol Renal Physiol, December 1, 1998; 275(6): F849 - F862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Vierhapper, P. Nowotny, and W. Waldhäusl Unchanged Testosterone Production Rates in Growth Hormone-Treated Healthy Men J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3735 - 3736. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Higashi, T. Oshima, N. Sasaki, N. Ishioka, Y. Nakano, R. Ozono, M. Yoshimura, K. Ishibashi, H. Matsuura, and G. Kajiyama Relationship Between Insulin Resistance and Endothelium-Dependent Vascular Relaxation in Patients With Essential Hypertension Hypertension, January 1, 1997; 29(1): 280 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Higashi, T. Oshima, M. Watanabe, H. Matsuura, and G. Kajiyama Renal Response to L-Arginine in Salt-Sensitive Patients With Essential Hypertension Hypertension, March 1, 1996; 27(3): 643 - 648. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
